Approved for use before surgery based on DESTINY-Breast11 Phase III trial Approved for use following surgery based on DESTINY-Breast05 Phase III trial...
Perioperative IMFINZI plus IMJUDO® (tremelimumab-actl) and neoadjuvant EV showed a statistically significant and clinically meaningful improvement in event-free survival and a favorable trend for overall...
ODAC overwhelming majority voted that TRUQAP plus abiraterone and ADT demonstrated a favorable benefit risk profile for patients based on the CAPItello-281 Phase III trial results ...
Strong revenue growth and positive readouts from high-value NMEs reinforce confidence in 2030 ambition
June S&P 500 E-Mini futures (ESM26) are up +0.14%, and June Nasdaq 100 E-Mini futures (NQM26) are up +0.27% this morning, buoyed by gains in technology stocks, while investors await the Federal Reserve’s...
Approval based on KALOS and LOGOS Phase III trials demonstrating statistically significant and clinically meaningful benefits of AstraZeneca’s single-inhaler fixed-dose triple therapy compared with inhaled...
First-in-class SAPHNELO Pen now offers greater flexibility and convenience, reaching a wider group of patients
Third positive pivotal Phase III clinical trial of AstraZeneca’s IL-33-targeting biologic further demonstrates its benefits in COPD
IMFINZI plus IMJUDO combined with lenvatinib and TACE demonstrated a statistically significant and clinically meaningful improvement in progression-free survival in embolization-eligible unresectable liver...
First-ever IL-33-targeting biologic to demonstrate statistically significant and highly clinically meaningful reductions in COPD exacerbations in two replicate Phase III clinical trials